Search the database for deliberate release of GM medicinal products

Displaying 1 - 6 of 6

EU record number	Title	Company / Sponsor	Treated organism	Genetic modification
MB-CART2019.1	A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant B-NHL	Miltenyi Biotech GmbH	Humans	CD19 and CD20 chimeric antigen receptor
ADP-0055-001	A phase I, ascending dose, to evaluate safety and efficacy of ADP A2M4CD8 in HLA-A2+ patients with MAGE-A4 psoitives tumors	Adaptimmune LLC	Humans	MAGE-A4 specific T cell receptor (TCR) with a CD8α co-receptor
Only notified under the "contained use" procedure. Dossier submitted on 14/10/2015.	A phase II, single-arm, multi-center trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia	Novartis Pharma Services AG	Humans	Chimeric antigen receptor against CD19
Only notified under the "contained use" procedure. Dossier submitted on 05/07/2005.	A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of Biobypass (ADGVVEGF121.10NH) delivered by NOGATM-guided/MYOSTARTM catheter in "no option" patients with class II-IV stable angina	GenVec, Inc.	Humans	human VEGF121
Only notified under the "contained use" procedure. Dossier submitted on 11/07/2002.	A European and Canadian multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 in patients with stable angina	Schering N.V./S.A.	Humans	human FGF-4
Only notified under the "contained use" procedure. Dossier submitted on 25/06/1999.	A phase I feasibility trial of a live, genetically modified Salmonella typhimurium bacillus (VNP20009) for the treatment of cancer by intra-tumoral injection	Vion Pharmaceuticals, Inc.	Humans	Not relevant